Dr. Eda Koculi As A Dead Box Protein

This paper hopes to share insight into the steps that are taken by companies, and the strenuous process behind developing an effective new drug.

Step 3: What protein will be your drug target? What property of that protein will you target? Design an assay/approach to identify an antidote for “degron”. (4 pts.)

With the huge diversity and changeability of human biology, it is impossible to imagine a reality without some mutations, changes, or issues in the organs and tissues of humans. Thus, it rightly follows that medications and pharmaceuticals have been created in an effort to counteract the various ailments and illnesses that people can experience. However, as time has gone on and these pharmaceuticals have become more and more high-tech, regulated, and trusted, they have also become incredibly commercialized. Worse still, medications have become incredibly expensive and can be unattainable for some people.

In humans/animals, the main cells that store fat for energy are adipocytes. These fat cells are found under the skin, in the abdominal cavity and surround major organs. The fatty tissue is the body’s main means of storing energy for long periods of time. Lipids, like triglycerides are stored in the adipocytes until ready to be used by the body for energy. Fat is broken down through metabolism in the mitochondria of the cell. The triglycerides are broken down into glycerol and 3 fatty acids. The glycerol can be easily converted to glyceraldehyde 3 phosphate, an intermediate of glycolysis. From there it can go through the Krebs Cycle and electron transport chain to make ATP. The 3 fatty acids can be broken

Cancer is a disease caused by an uncontrolled division of abnormal cells. The DNA sequence in cells can be changed as a result of copying errors during replication. If these changes whatever their cause are left uncorrected, both growing and non-growing somatic cells might gain many mutations that they could no longer function. The relevance of DNA damage and repair to the generation of cancer was obvious when it was recognized that everything that causes cancer also cause a change in the DNA sequence. Tumor suppressor genes are protective genes and normally they limit cell growth by monitoring the speed of cell division, repair mismatched DNA and control when a cell dies. When a tumor suppressor gene is mutated cells grow

Tickoo, S. (2002). Drosophila melanogaster as a model system for drug discovery and pathway screening. Current Opinion in Pharmacology, 2(5),

Compound 3a was selected by the National Cancer Institute (NCI) USA for anticancer screening with the NCI code D-785902/1. Compound 3c was found in the already tested cancer candidates in the NCI data base under NCI code NSC: 650353[42]. Both candidates were screened on human tumour cell lines at 10-5 M at the 60-Cell-Line Screenings of the Developmental Therapeutics Program (DTP) of the National Cancer Institute (NCI, Bethesda, Maryland, USA) under the drug discovery program of the NCI. The 60-cell-line-screening of the NCI includes 60 different tumour cell lines, the nine various organs and tumour types derived (leukaemia, non-small-cell lung cancer, colon cancer, CNS cancer, melanoma,

This project seeks to provide a brief overview of what a new drug has to go through before it hits the streetsstarting with the manufacture, preclinical or clinical trials, documentation, registration, review, approval, marketing, &distribution; focusing on tests they have to hurdle. Another aim would be to identifya drug that binds itself to the SGLT2 & inhibits its function. The researcher has found that Dapagliflozin of the Gliflozin class of antidiabetic medications is anSGLT2 inhibitor. This paper will define keywords, explain the action, enumerate preclinical &clinical trials that have to be undergone before the FDA deems it safe for human consumption; with the ultimate goal of getting the product approved, marketed, &distributed in the US& elsewhere. There are no participants [animal or human] in this report. This

While the steps to bring a new drug to market may seem extensive and costly, they are a necessity. Clinical drug trials provide options for people with diseases while also allowing doctors to improve the way they diagnose and treat these diseases. The process is long, but the benefits that new drugs have to offer, is

The cornerstone of modern medicine is the ability to treat an illness in the absence of a concrete cure. In the case of detrimental diseases such as cancer or HIV, the lack of a cure has not impeded the progress of treatment and prolonging of life. However, there does exist a disease which until recently had no significant treatment: Duchenne Muscular Dystrophy (DMD). Modern gene therapy has provided a chance to cure this illness. DMD is a sex linked disease affecting 1 in 3500 male births. It is caused by a mutation in the dystrophin gene, which is needed for proper skeletal muscle function. The Dystrophin Gene is the largest known human gene, located on the short arm of the X chromosome specifically at the genetic locus XP21. It is composed

For the second part of the experiment, one had to use the knowledge learn from viewing protein molecules in FirstGlance in Jmol to analyze the protein PDB ID: 4EEY. The analysis of this protein was done using the RSCB protein data bank (PDB) at (http://www.rcsb.org/pdb/home/home.do).2

Over the years, scientists have been instrumental in discovering and developing new drugs that save thousands of people’s lives. This significantly improves life as we know it on Earth. So basically, this topic is on a big in-depth study of drugs and medications.

These two proteins interact and act on the proteins p53 and Rb which are tumor suppressor proteins. The outcome of their interaction is the inactivation of these proteins in the host.

As mentioned in class, as well as in the required Krishna (2008) article, the drug development and approval process is an extensive and costly endeavor. The goal of experimental medicine is to increase the efficiency of drug development by providing a better understanding of the drug’s mechanism(s) of action, dose response, efficacy, and safety, allowing the process to be accelerated for the most promising and efficacious candidates (Krishna, Herman, & Wagner, 2008).

Drug research is connected to a range of academic studies such as biology, pharmacology, medicinal chemistry and toxicology. Pharmaceutical researchers can design novel therapeutic drugs based on these studies above. The invention of new drug can be divided by function into two stages: drug discovery and drug development. Drug discovery is the process by which a new drug candidate is found and identified. Distinctively, bringing a new drug candidate to the market through clinical trials is called drug development. The first part of this essay provides an overview of drug discovery and pre-clinical research and development